Research paperSynthesis and biological evaluation of quinazoline derivatives – A SAR study of novel inhibitors of ABCG2
Graphical abstract
Introduction
ATP-Binding cassette (ABC) transport proteins are found among eukaryotic and prokaryotic organisms [1]. In eukaryota they are expressed in different tissues where they provide membrane transport of nutrients and are responsible for an active efflux of different molecules upon ATP hydrolysis, protecting the cells from potentially harmful compounds [2,3]. Human ABC transport proteins form a superfamily of 48 members, classified into seven subfamilies ABC A to ABC G [[4], [5], [6]]. The Breast Cancer Resistance Protein (BCRP, ABCG2) for instance is expressed amongst others in tissues like the gut, bile, canaliculi, placenta, blood-testis, and blood-brain barriers excreting and limiting absorption of potentially harmful substrate molecules [7,8]. ABCG2 is one of three major members of the ABC transport protein family besides P-glycoprotein (P-gp, ABCB1) and multidrug resistance associated protein 1 (MRP1, ABCC1), which are often associated with the occurrence of multidrug resistance (MDR) in cancer [4,[9], [10], [11]]. Breast Cancer Resistance Protein was discovered in 1998 by Doyle et al. when they selected a human breast cancer cell line for doxorubicin resistance in the presence of the ABCB1 inhibitor verapamil [12,13]. More cytostatic drugs like the anthracene derivative mitoxantrone (MX) or the active metabolite of irinotecan, namely SN-38, were identified as substrates of ABCG2 [14,15]. Therefore, a chemotherapeutic therapy might lack effectiveness due to overexpression of ABCG2, leading to a low intracellular concentration of the cytostatic. High expression rates of ABCG2 were for instance found in solid tumors and hematopoietic tumors [16]. A possible way to resensitize such cancer cells could be the co-administration of potent inhibitors of ABCG2.
The first potent inhibitor was discovered and isolated from Aspergillus fumigatus, and named fumitremorgin C (FTC). Despite its high potency, FTC never found clinical application owing to neurotoxic side effects [17]. More promising was the second generation inhibitor Ko143, exhibiting a high potency together with selectivity in the submicromolar range toward ABCG2 [18,19]. The tyrosine kinase inhibitor gefitinib is used in clinical application for the treatment of non-small cell lung carcinoma (NSCLC). It was found that co-administration with topoisomerase I inhibitors was an effective approach to overcome the resistance of ABCG2 overexpressing cells [20]. However, only few potent and selective inhibitors of ABCG2 have been described yet [21].
Our workgroup decided to modify the structure of gefitinib, to increase its relatively low inhibitory potency toward ABCG2. First step was to start with the underlying quinazoline scaffold introducing a phenyl moiety at position 2 und to introduce various substituents at the aniline linker at position 4. First results from the Hoechst 33342 accumulation assay with ABCG2 overexpressing cells were promising, yielding several compounds with higher potencies than Ko143, one of the most potent inhibitor of ABCG2 known to date [[22], [23], [24], [25], [26]]. In our most recent study we investigated a modification of the quinazoline scaffold using a pyrido[2,3-d]pyrimidine structure [27]. We found an enantiotopic relation of the inhibitory activities between those scaffolds leading to several highly potent derivatives. Also, the intrinsic cytotoxicities of these new compounds were low.
In the present study, we decided to investigate different modifications of our basic 4-anilino-2-phenylquinazoline scaffold. We replaced the aromatic residue at position 2 by five-membered heteroaromatic moieties as well as hydrogen to determine the impact of the substitution at this position on the inhibitory activity toward ABCG2. Also, we altered the 4-amino linker by replacing it by oxygen or sulphur. Furthermore, the linker was replaced by an amido group. Based on the results from the oxygen and sulphur linkers we methylated the amino linker to investigate the importance of a H-donor function on inhibitory activity.
With these new insights into the structure-activity relationship (SAR) of this novel class of inhibitors new tailored inhibitors of ABCG2 can be designed.
Section snippets
Chemistry
A brief description of the synthetic route for all compounds is presented in Scheme 1.
Quinazolinone derivatives containing a five-membered aromatic ring at position 2 were synthesized via cyclic condensation from anthranilamide together with thiophene-2-carbaldehyde or 1H-pyrrole-2-carbaldehyde to yield the corresponding precursor 1 or 2. Chlorination of the carbonyl function at position 4 was achieved by reaction with POCl3 to yield 3 and 4. The 2-substituted-4-chloroquinazoline derivatives
Conclusions
In this study several modifications of the quinazoline scaffold were carried out. The first series based on scaffold A contained the five-membered heterocycles thiophene and pyrrole at position 2. For both heterocycles the highest inhibitory activity in the Hoechst 33342 accumulation assay was obtained with a 3-cyano substituent of the anilino linker at position 4 (see compound 7; IC50: 178 nM and 11; IC50: 156 nM), revealing even higher potencies toward ABCG2 than standard inhibitor Ko143 (IC50
Materials
Chemicals were purchased from Acros Organics (Geel, Belgium), Alfa Aesar (Karlsruhe, Germany), Sigma Aldrich (Steinheim, Germany) or Merck (Darmstadt, Germany) and used without further purification. Reactions in the microwave were performed with 50 mL vials using with a CEM Discover SP (CEM GmbH, Kamp-Lintfort, Germany). Reaction progress was monitored using thin layer chromatography (TLC) with an aluminium plate coated with silica gel 60 F254 (Merck Millipore, Billerica, MA, USA). As eluent a
References (51)
- et al.
Purification and structural analyses of ABCG2
Adv. Drug Deliv. Rev.
(2009) - et al.
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
Biochem. Pharmacol.
(2012) - et al.
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Biochim. Biophys. Acta
(1976) - et al.
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2)
Bioorg. Med. Chem.
(2013) - et al.
4-Substituted-2-phenylquinazolines as inhibitors of BCRP, bioorg
Med. Chem. Lett.
(2012) - et al.
Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2)
Eur. J. Med. Chem.
(2017) - et al.
ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines
Biochim. Biophys. Acta
(1997) - et al.
Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter modulation of substrate specificity by a point mutation
J. Biol. Chem.
(2002) - et al.
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2)
Bioorg. Med. Chem.
(2008) - et al.
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP)
Bioorg. Med. Chem.
(2011)
New functional assay of P-glycoprotein activity using Hoechst 33342
Bioorg. Med. Chem.
Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein
Bioorg. Med. Chem.
Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation
Eur. J. Pharmaceut. Sci.
Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2
Eur. J. Med. Chem.
A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins
Bioorg. Med. Chem. Lett
Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators
Bioorg. Med. Chem.
Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity
Biochim. Biophys. Acta
Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase
J. Biol. Chem.
The evolutionary repertoires of the eukaryotic-type ABC transporters in terms of the phylogeny of ATP-binding domains in eukaryotes and prokaryotes
Mol. Biol. Evol.
Human ABCG2: structure, function, and its role in multidrug resistance
Int. J. Biochem. Mol. Biol.
Structure and mechanism of ABC transporters
F1000Prime Rep.
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport - an update
AAPS J.
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone resistant cells: demonstration of homology to ABC transport genes
Cancer Res.
Expression of a multidrug-resistance gene in human tumors and tissues
Proc. Natl. Acad. Sci. U. S. A
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
Science
Cited by (31)
Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors
2023, European Journal of Medicinal ChemistryTargeting ABCG2 transporter to enhance 5-aminolevulinic acid for tumor visualization and photodynamic therapy
2023, Biochemical PharmacologyUpdated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development
2022, European Journal of Medicinal ChemistryIdentification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)urea as a potential anti-colorectal cancer agent
2022, European Journal of Medicinal ChemistryCitation Excerpt :Starting materials 2a-d were reacted with substituted 4-nitrophenol or 4-nitrophenylamine in PhCl to afford various quinoline derivatives 3a-b and 3d-i (Scheme 1). Intermediate 3b was methylated by the use of CH3I and NaH to yield 3c [42]. Reduction of the nitro groups of 3a-i via iron powder and HOAc in 90% EtOH provided the amino precursors 4a-i. Subsequently, the amines 4a-i were acidylated with phenyl chloroformate in the presence of pyridine to facilitate 5a-i which were suffered hydrazinolysis reactions with 80% hydrazine hydrate with vigorous agitation.